Muaiad Kittaneh, Global Head of RandD and Scintific Strategy at Syneos Health, shared a post on LinkedIn by Syneos Health, adding:
“As we head into ASCO26, this is the type of conversation that matters in immuno-oncology (IO): not only what biology we target, but how we translate that biology into trials that are executable, patient-centered, and clinically meaningful.
The next generation of IO development will depend on moving beyond broad immune activation toward more precise orchestration:
- matching the right immune contexture to the right patient population
- understanding adaptive resistance earlier, not after failure
- designing combinations with biological rationale, not just additive hope
- using biomarkers like ctDNA/MRD and longitudinal monitoring to inform smarter decisions (may be in real time )
- keeping trial design operationally realistic so promising science can actually reach patients
For me, the key question is no longer whether IO remains important. It clearly does. The question is whether we can make it more precise, more biologically informed, and more clinically disciplined , especially in tumor types where benefit has been inconsistent or difficult to sustain.
Looking forward to the discussions at ASCO26 and to connecting with colleagues focused on turning immune complexity into meaningful clinical impact.
Download the full white paper here.”
Quoting Syneos Health‘s post:
“Headed to ASCO 2026? So are we.
As the immuno-oncology landscape continues to evolve, success increasingly depends on matching the right biology to the right patient at the right time and turning scientific complexity into meaningful clinical impact.
Ahead of ASCO26, explore our latest Insights Hub whitepaper on the future of precision orchestration in immuno-oncology development, from overcoming immune exhaustion to monitoring adaptive resistance and optimizing combination strategies.
Download the full whitepaper here
Meet with our team onsite to discuss how we’re helping design the next generation of oncology trials here.”
Other articles about Immuno-Oncology (IO) on OncoDaily.